The Latest Cardiac and Vascular News
PHILADELPHIA, Aug. 25, 2022 (GLOBE NEWSWIRE) — ŌNŌCOR LLC announced the use of the ŌNŌ endovascular retrieval system to remove a large central-line-associated thrombus from the right atrium in a teenage patient. The team at Children’s Hospital Los Angeles (CHLA, @ChildrensLA), led by Dr. Darren Berman, Director of Congenital Interventional Catheterization with CHLA’s Heart Institute, […]
— Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses — — Data Presented During Late-Breaking Science Session at European Society of Cardiology (ESC) Congress 2022 in Barcelona — DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 26, 2022 (GLOBE NEWSWIRE) — Amarin […]
Treatment with ninerafaxstat significantly improved cardiac energetics, steatosis and left ventricular (LV) diastolic function in patients with type-2 diabetes mellitus (T2DM) and obesity BOSTON, Mass., Aug. 26, 2022 (GLOBE NEWSWIRE) — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced positive […]
ANN ARBOR, Mich., Aug. 26, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that bempedoic acid (NEXLETOL®) is now recommended as an important oral non-statin therapy for LDL-cholesterol (LDL-C) lowering in the management of atherosclerotic cardiovascular disease (ASCVD) by the American College of Cardiology (ACC) task force on expert […]
MADRID–(BUSINESS WIRE)–The polypill developed by the CNIC and Ferrer, which includes three drugs (aspirin, an angiotensin-converting enzyme (ACE) inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack. The polypill reduces mortality from cardiovascular causes in this population by 33%. This is […]
-Results featured in a late-breaking oral presentation- -Treatment with pegozafermin demonstrated consistent and significant benefit in triglyceride (TG) reduction as well as improvements in liver fat and glycemic control- -Positive data support the advancement into a Phase 3 trial in SHTG- SAN FRANCISCO, Aug. 26, 2022 (GLOBE NEWSWIRE) — 89bio, […]
Kaiser Permanente study showed patients in home-based cardiac rehabilitation had fewer hospitalizations than those in center-based cardiac rehabilitation PASADENA, Calif., Aug. 25, 2022 /PRNewswire/ — Patients who participated in in-home cardiac rehabilitation had fewer hospitalizations over 12 months than patients who participated in center-based cardiac rehabilitation, according to a Kaiser Permanente study published August […]
SUNNYVALE, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with BlueRock Therapeutics LP for the delivery of BlueRock’s cell therapy product candidates for the treatment of heart failure utilizing BioCardia’s minimally invasive biotherapeutic delivery product candidates. “We look forward to […]
First Dedicated Leaflet Splitting Device for Preventing LVOT Obstruction REHOVOT, ISRAEL / ACCESSWIRE / August 22, 2022 / Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based solutions for treating heart valves, announced today a successful First-In-Human treatment of the mitral valve with the ShortCut™ Mitral device in Europe. […]
CAMBRIDGE, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced new preclinical data supporting the nomination of the company’s second product candidate, VERVE-201. VERVE-201 is designed to permanently turn […]
